Ablukast

Ablukast (INN) is an experimental drug that is a leukotriene antagonist. It was investigated for potential applications in the treatment of inflammatory conditions, including asthma, skin disorders, and inflammatory bowel disease.[1][2] It reached Phase III clinical trials, but development was discontinued in 1996.[2]

Ablukast
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • 6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]chroman-2-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H34O8
Molar mass498.572 g·mol−1
3D model (JSmol)
  • CCCC1=C(C=CC(=C1O)C(=O)C)OCCCCCOC2=CC3=C(CCC(O3)C(=O)O)C=C2C(=O)C
  • InChI=1S/C28H34O8/c1-4-8-21-23(12-10-20(17(2)29)27(21)31)34-13-6-5-7-14-35-26-16-25-19(15-22(26)18(3)30)9-11-24(36-25)28(32)33/h10,12,15-16,24,31H,4-9,11,13-14H2,1-3H3,(H,32,33) checkY
  • Key:FGGYJWZYDAROFF-UHFFFAOYSA-N checkY
  (verify)

References
  1. Rosenbach T, Csatò M, Czarnetzki BM (January 1988). "Studies on the role of leukotrienes in murine allergic and irritant contact dermatitis". The British Journal of Dermatology. 118 (1): 1–6. doi:10.1111/j.1365-2133.1988.tb01743.x. PMID 2829957. S2CID 1164113.
  2. "Ablukast". Adis Insight.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.